¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"sexual activity"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
À̰ÍÀ» ¿øÇϼ̽À´Ï±î?
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • sexual assault
    ¼ºÆøÇà
  • sexual aversion disorder
    ¼ºÇø¿ÀÀå¾Ö
  • sexual behavior
    ¼ºÀûÇൿ
  • sexual bondage
    ¼º¼Ó¹Ú
  • sexual cell
    Á¾ÀÚ¼¼Æ÷, »ý½Ä¼¼Æ÷
  • sexual cord
    žÆÁ¤¼¼°ü, ¼º»è
  • sexual cycle
    ¼ºÁÖ±â
  • sexual desire
    ¼º¿å
  • sexual desire disorder
    ¼º¿åÀå¾Ö
  • sexual development
    ¼º±â´É¹ß´Þ
  • sexual deviation
    ¼ºµµÂø(Áõ)
  • sexual disinhibition
    ¼ºÀûÅ»¾ïÁ¦
  • sexual disorder
    ¼º(Àû)Àå¾Ö
  • sexual drive
    ¼º¿åµ¿
  • sexual dysfunction
    ¼º±â´ÉÀå¾Ö
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • sexual bondage
    ¼º¼Ó¹Ú
  • sexual cell
    (¢¡germ cell) Á¾ÀÚ¼¼Æ÷, ¹è¾Æ¼¼Æ÷, »ý½Ä¼¼Æ÷
  • sexual cord
    žÆÁ¤¼¼°ü
  • sexual cycle
    ¼ºÁÖ±â
  • female sexual arousal disorder
    ¿©¼º¼ºÀûÈïºÐÀå¾Ö
  • hypoactive sexual desire disorder
    ¼º¿å°¨¼Òº´, ¼º¿å°¨¼ÒÀå¾Ö
  • sexual desire
    ¼º¿å
  • sexual development
    ¼º¹ß´Þ, ¼º±â´É¹ß´Þ
  • sexual deviation
    ¼ºµµÂø(Áõ)
  • sexual disinhibition
    ¼ºÅ»¾ïÁ¦
  • sexual disorder
    ¼ºÀå¾Ö
  • sexual drive
    ¼º¿åµ¿
  • sexual dysfunction
    ¼º±â´ÉÀå¾Ö
  • sexual arousal disorder
    ¼ºÈïºÐÀå¾Ö
  • sexual aversion disorder
    ¼ºÇø¿ÀÀå¾Ö, ¼ºÇø¿Àº´
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • intrinsic sympathomimetic activity
    ³»Àμº ±³°¨½Å°æÀ¯»çÀÛ¿ë.
  • intrinsic sympathomimetic activity
    ³»Àμº ±³°¨½Å°æÀÚ±ØÀÛ¿ë.[¾à¸®]³» ÀÎ<Àç>¼º ±³°¨½Å°æÀ¯»çȰ¼º.
  • laboratory activity
    °Ë»ç½ÇȰµ¿
  • lipase activity
    ¸®ÆÄÁ¦ Ȱ¼ºµµ
  • lipolytic activity
    ÁöÁúºÐÇØÀûÇØ.
  • mental activity
    Á¤½ÅȰµ¿(¡­üÀÔÑ).
  • molar activity
    ¸ôȰ¼º(¡­üÀàõ).
  • multiplication stimulating activity
    Áõ½ÄÀÚ±ØÈ°µ¿
  • muscular activity
    ±ÙÀ°È°µ¿.
  • muscular activity
    ±ÙÀ° Ȱµ¿.
  • non-suppressible insulin-like activity
    ºñ¾ïÁ¦Àν¶¸°¾ç Ȱ¼º
  • osmotic activity
    »ïÅõÀû Ȱµ¿µµ(¡­îÜüÀÔÑöô).
  • partial agonistic activity
    ºÎºÐÈ¿´É(Àû) Ȱ¼º, ºÎºÐÈ¿Çö(Àû) Ȱ¼º.
  • phagocytic activity
    ½Ä¼¼Æ÷´É(¡­Òö).
  • plasma histaminase activity
    Ç÷ÀåÈ÷½ºÅ¸¹Ì³ª¾ÆÁ¦È°¼ºµµ.
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
ISE inhibited sexual excitement; International Society of Endocrinology; International Society of Endosc...
PLISSIT permission to be sexual, limited information, specific suggestions, intensive therapy
SAI Self-Analysis Inventory; Sexual Arousability Inventory; Social Adequacy Index; suppressor of anchora...
SCT secretin; sex chromatin test; sexual compatibility test; sickle-cell trait; sperm cytotoxicity; spin...
SDS same day surgery; school dental services; self-rating depression scale; sensory deprivation syndrome...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
ADNF Activity-dependent neurotrophic factor
ADA Adenosine Deaminase activity
ALT Alanine aminotransferase activity
ALP Alkaline phosphatase activity
AP Alkaline phosphatase activity
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • maintained activity
    Ȱ¼º À¯Áö
  • mental activity
    Á¤½Å Ȱµ¿
  • molar activity
    ¸ô Ȱ¼º
  • muscle activity
    ±Ù Ȱ¼º
  • muscular activity
    ±ÙÀ° Ȱµ¿, ±Ù Ȱ¼ºµµ
  • neuromuscular reflex activity
    ±Ù½Å°æ ¹Ý»ç Ȱµ¿
  • nociceptor activity
    Ä§ÇØ ¼ö¿ëü Ȱ¼º, À¯ÇØ ¼ö¿ë±â Ȱ¼º
  • partial agonistic activity
    ºÎºÐ È¿´É, ºÎºÐ È¿´ÉÀû Ȱ¼º, ºÎºÐ È¿ÇöÀû Ȱ¼º
  • persistent activity
    Áö¼ÓÀûÀΠȰ¼º
  • phagocytic activity
    ½Ä¼¼Æ÷´É
  • play activity
    ³îÀÌ
  • postural electromyographic activity
    ÀÚ¼¼¼º ±ÙÀüµµ Ȱ¼º
  • reflex activity
    ¹Ý»ç Ȱµ¿
  • seizure activity
    ¹ßÀÛ¼º Ȱµ¿
  • serum diastase activity
    Ç÷û µð¾Æ½ºÅ¸Á¦Ä¡
    Ç÷û¿¡ ÇÔÀ¯µÈ ¾Æ¹Ð¶ó¾ÆÁ¦ÀÇ ¾çÀ» ³ªÅ¸³»´Âµ¥ »ç¿ëÇÑ´Ù.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
motor activity The physical activity of an organism as a behavioural phenomenon.
(12 Dec 1998)
complement haemolytic activity assay Usual screening assay for complement. Dilutions of the serum to be tested are added to antibody-coated erythrocytes and the percentage of lysis is measured. The values are expressed by ch50, haemolytic complement units per milliliter, which is the dilution of serum required to lyse 50 percent of the erythrocytes in the assay.
(12 Dec 1998)
plasma renin activity The estimation of renin in plasma by measuring the rate of formation of angiotensin I or II.
(05 Mar 2000)
solar activity Any type of variation in the appearance of energy output of the sun.
(12 Dec 1998)
specific activity 1. <chemistry> The number of activity units (whatever is appropriate) per unit of mass, volume or molarity.
2. <radiobiology> Total activity of a given nuclide per gram of a compound, element or radioactive nuclide. Perhaps most often usage, in the context of radiochemicals, the number of microcuries per micromole.
(16 Dec 1997)
structure activity analysis Study in which systematic variation in the structure of a compound is correlated with its activity, in an attempt to determine the characteristics of the (receptor) site at which it acts.
(18 Nov 1997)
structure-activity relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Other factors contributing to structure-activity relationship include chemical reactivity, electronic effects, resonance, and inductive effects.
(12 Dec 1998)
nonsuppressible insulin-like activity A blood protein (nsila) which mimics the biological activity of insulin in serum, but is not suppressed by insulin antibodies. During acid-ethanol extraction of cohn fraction III, 10% of the activity is found in the supernatant (nsila-s) and the remaining activity in the precipitate (nsila-p). The latter is a large molecular compound, much less stable than the soluble fraction. Nsila-s is a more potent growth factor than insulin and exhibits sulfation activity.
(12 Dec 1998)
drug activity A measure of the physiological response a drug produces. A less active drug produces less response (and visa versa).
(12 Dec 1998)
insulin-like activity A measure of substances, usually in plasma, that exert biologic effects similar to those of insulin in various bioassays; sometimes used as a measure of plasma insulin concentrations; always gives higher values than immunochemical techniques for the measurement of insulin.
(05 Mar 2000)
intrinsic sympathomimetic activity The property of a drug that causes activation of adrenergic receptors so as to produce effects similar to stimulation of the sympathetic nervous system.
(05 Mar 2000)
optical activity The ability of a material to rotate the plane of polarized light.
(09 Oct 1997)
triggered activity One or a series of spontaneously generated heart beats originating from an action potential that produces an after-depolarisation which reaches activation threshold.
(05 Mar 2000)
unit of thyrotrophic activity The activity of an amount of an extract of the anterior lobe of the hypophysis which, given daily for 5 days, will cause the thyroid of a guinea pig (weighing 200 g) to reach a weight of 600 mg.
(05 Mar 2000)
zone of polarizing activity <cell biology> The small group of mesenchyme cells in avian limb buds that is located at the posterior margin of the developing bud and that produces a substance, possibly retinoic acid, that provides positional information to the developing limb bud.
(18 Nov 1997)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
ÅëÇÕ°Ë»ö ¿Ï·á